Integra LifeSciences (NASDAQ:IART) Hits New 1-Year High – Time to Buy?

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s stock price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $18.19 and last traded at $17.9450, with a volume of 27101 shares changing hands. The stock had previously closed at $17.77.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and upped their price objective for the company from $11.00 to $16.00 in a research report on Thursday, May 28th. Argus restated a “hold” rating on shares of Integra LifeSciences in a research report on Wednesday, April 15th. Truist Financial reduced their price objective on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a research report on Wednesday, April 15th. Wall Street Zen upgraded Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, Wells Fargo & Company upped their price objective on Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. Four investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $14.00.

Integra LifeSciences Price Performance

The company has a fifty day simple moving average of $13.60 and a two-hundred day simple moving average of $12.26. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of -2.74, a P/E/G ratio of 1.21 and a beta of 1.24. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. The firm had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The firm’s quarterly revenue was up 2.4% on a year-over-year basis. During the same period last year, the company earned $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.44 earnings per share for the current year.

Institutional Trading of Integra LifeSciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Glenmede Trust Co. NA grew its holdings in Integra LifeSciences by 27.4% in the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock valued at $9,276,000 after buying an additional 211,774 shares during the period. Access Investment Management LLC grew its holdings in Integra LifeSciences by 72.0% in the 1st quarter. Access Investment Management LLC now owns 640,535 shares of the life sciences company’s stock valued at $6,034,000 after buying an additional 268,085 shares during the period. Bank of America Corp DE grew its holdings in Integra LifeSciences by 71.4% in the 1st quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock valued at $13,325,000 after buying an additional 589,408 shares during the period. Amundi grew its holdings in Integra LifeSciences by 80.8% in the 1st quarter. Amundi now owns 19,430 shares of the life sciences company’s stock valued at $183,000 after buying an additional 8,681 shares during the period. Finally, Maverick Capital Ltd. purchased a new stake in Integra LifeSciences in the 1st quarter valued at about $679,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.